Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-04-17Clinical Trial Update: Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) [Phase 2]
A Phase 2 clinical trial evaluating pembrolizumab as neoadjuvant therapy for resectable Stage IA3 to IIA non-small cell lung cancer was term…
-
CLINICAL_TRIALS withdrawal · 2026-04-08Clinical Trial Update: Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC [Phase 1, Phase 2]
A Phase 1/2 trial investigating SHR-A1921 combined with Adebrelimab and SHR-8068, with or without carboplatin, for advanced non-small cell l…
-
CLINICAL_TRIALS withdrawal · 2026-03-16Clinical Trial Update: Managed Access Programs for INC280, Capmatinib
The document reports that the managed access program for capmatinib (INC280) is no longer available.
-
CLINICAL_TRIALS withdrawal · 2026-03-13Clinical Trial Update: Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC [Phase 1, Phase 2]
A Phase 1/2 trial evaluating Vudalimab or pembrolizumab with chemotherapy as first-line treatment for advanced nonsquamous non-small cell lu…
-
CLINICAL_TRIALS withdrawal · 2026-02-23Clinical Trial Update: CISH Inactivated TILs in the Treatment of NSCLC [Phase 1, Phase 2]
A Phase 1/2 trial evaluating CISH-inactivated tumor-infiltrating lymphocytes for non-small cell lung cancer has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2026-02-05Clinical Trial Update: Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer [NA]
A clinical trial evaluating daily adaptive radiation therapy for Stage III non-small cell lung cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-11-21Clinical Trial Update: A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 trial evaluating BT-001 alone and in combination with pembrolizumab in metastatic or advanced solid tumors has been terminated.
-
EMA withdrawal · 2025-11-11EMA Application withdrawn: Datopotamab deruxtecan Daiichi Sankyo (datopotamab deruxtecan) — Daiichi Sankyo Europe GmbH
EMA has withdrawn the marketing authorization application for datopotamab deruxtecan by Daiichi Sankyo Europe GmbH for non-small cell lung c…
-
CLINICAL_TRIALS withdrawal · 2025-09-15Clinical Trial Update: Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab [Phase 2]
Phase 2 neoadjuvant trial of adagrasib (MRTX849) with or without nivolumab in resectable non-small cell lung cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-09-10Clinical Trial Update: Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung Cancer [Phase 2]
A Phase 2 trial evaluating concomitant chemo-radiotherapy for locally advanced non-small cell lung cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-09-02Clinical Trial Update: Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures [Phase 2]
Phase 2 trial targeting MDMD and PD-1 in tumors with tertiary lymphoid structures has been withdrawn; the study covered soft tissue sarcoma,…
-
CLINICAL_TRIALS withdrawal · 2025-08-22Clinical Trial Update: Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer [Phase 2]
A Phase 2 trial evaluating Luveltamab Tazevibulin in adults with advanced or metastatic non-small cell lung cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-08-13Clinical Trial Update: Expanded Access of Sotorasib
Expanded access program for sotorasib (Amgen) in non-small cell lung cancer is no longer available.
-
CLINICAL_TRIALS withdrawal · 2025-08-08Clinical Trial Update: Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases [Phase 2]
A Phase 2 trial of Datopotamab Deruxtecan (Dato-DXd) for non-small cell lung cancer with active brain metastases has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-07-30Clinical Trial Update: HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Alaunos Therapeutics reports termination of a Phase I/II autologous TCR-T cell trial across several solid tumors. The study focused on HLA t…
-
CLINICAL_TRIALS withdrawal · 2025-07-28Clinical Trial Update: Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients [NA]
A clinical trial evaluating Shu Yu Wan, a Chinese herbal formula, for metastatic non-small cell lung cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-07-01Clinical Trial Update: A Study to Investigate LYL797 in Adults With Solid Tumors [Phase 1]
Lyell Immunopharma's Phase 1 study of LYL797 in adults with solid tumors has been terminated.
-
CLINICAL_TRIALS withdrawal · 2025-06-26Clinical Trial Update: Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) [Phase 3]
Phase 3 trial comparing FYB206 to pembrolizumab (Keytruda) as add-on to chemotherapy in non-squamous non-small cell lung cancer has been ter…
-
CLINICAL_TRIALS withdrawal · 2025-06-08Clinical Trial Update: Medical Access Program for Patritumab Deruxtecan
The Medical Access Program for patritumab deruxtecan in EGFR-mutated non-small cell lung cancer is no longer available.
-
CLINICAL_TRIALS withdrawal · 2025-05-26Clinical Trial Update: Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer [Phase 2]
A Phase 2 trial evaluating cemiplimab for untreated brain metastases in patients with PD-L1 >= 50% non-small cell lung cancer has been withd…
-
CLINICAL_TRIALS withdrawal · 2025-05-15Clinical Trial Update: Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies
The trial examining biopsy specimens to study responses to PD-1 or PD-L1 therapies has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-04-24Clinical Trial Update: Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2) [Phase 2]
The BrightStar-2 Phase 2 trial evaluating brigatinib in combination with chemotherapy or local consolidation therapy for ALK-positive advanc…
-
CLINICAL_TRIALS withdrawal · 2025-04-17Clinical Trial Update: Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma [Phase 2]
Phase 2 trial evaluating local consolidative radiotherapy for oligoprogressive non-small cell lung cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-04-16Clinical Trial Update: A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants [Phase 1]
This clinical trial update reports the withdrawal of a Phase 1 study evaluating AN0025 in combination with chemoradiation therapy for stage …
-
CLINICAL_TRIALS withdrawal · 2025-04-10Clinical Trial Update: A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells
A clinical trial evaluating A2R and ectonucleotidases expression in circulating tumor cells from non-small cell lung cancer has been withdra…